Evolus (NASDAQ:EOLS) Stock Gets Price Target Bump from BTIG Research

Evolus (NASDAQ:EOLS) had its price objective hoisted by stock analysts at BTIG Research from $13.00 to $15.00 in a report released on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research‘s target price would indicate a potential upside of 120.59% from the company’s previous close.

EOLS has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evolus in a research note on Friday, September 11th. Wall Street Zen raised Evolus from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, HC Wainwright restated a “buy” rating and issued a $13.00 price objective on shares of Evolus in a research note on Tuesday, August 25th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Evolus currently has an average rating of “Moderate Buy” and an average target price of $15.00.

Evolus Stock Performance

EOLS remained flat at $6.80 during trading on Thursday. The company had a trading volume of 1,521,612 shares, compared to its average volume of 709,793. The firm has a market capitalization of $449.14 million, a P/E ratio of -14.47 and a beta of 1.38. Evolus has a 1 year low of $3.86 and a 1 year high of $9.31. The company has a 50-day moving average of $7.81 and a 200-day moving average of $6.31.

Insiders Place Their Bets

In other Evolus news, insider David Moatazedi sold 105,108 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total value of $950,176.32. Following the completion of the transaction, the insider directly owned 499,592 shares of the company’s stock, valued at approximately $4,516,311.68. The trade was a 17.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. GAMMA Investing LLC grew its holdings in shares of Evolus by 65.6% in the 3rd quarter. GAMMA Investing LLC now owns 3,288 shares of the company’s stock valued at $26,000 after acquiring an additional 1,303 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Evolus by 15.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,052 shares of the company’s stock valued at $96,000 after purchasing an additional 1,571 shares during the last quarter. Krilogy Financial LLC boosted its position in Evolus by 20.0% during the third quarter. Krilogy Financial LLC now owns 13,907 shares of the company’s stock valued at $108,000 after purchasing an additional 2,320 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Evolus during the third quarter valued at approximately $27,000. Finally, Bank of New York Mellon Corp grew its stake in Evolus by 3.9% in the first quarter. Bank of New York Mellon Corp now owns 143,164 shares of the company’s stock valued at $588,000 after purchasing an additional 5,367 shares in the last quarter. 90.69% of the stock is owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc is a commercial-stage medical aesthetics company focused on developing and marketing products for physicians and other licensed aesthetic providers. The company’s business is centered on minimally invasive treatments intended to address facial lines, wrinkles and other visible signs of aging.

Evolus’ primary product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved by the U.S. Food and Drug Administration for the temporary improvement of moderate to severe glabellar lines, commonly known as “frown lines,” in adults.